West Virginia tramadol dispensing fell overall, but county-level patterns stayed uneven

West Virginia’s tramadol market moved in one direction over the 2015 to 2022 period: downward. Yet the decline was not evenly shared across counties, and the dispensing map still tracked signs of underlying community disadvantage, from worse self-rated health to higher uninsured rates and lower physical activity.

The analysis focused on tramadol dispensing as an opioid-specific signal rather than as a generic pain medication trend. That distinction matters at the bedside and in policy circles because tramadol carries opioid liability while also behaving pharmacologically like a mixed-mechanism analgesic, with weak µ-opioid receptor agonism and inhibition of serotonin and norepinephrine reuptake. Its analgesic effect depends heavily on CYP2D6 conversion to O-desmethyltramadol, so real-world response can vary widely across patients and co-medication profiles. In a state that has already tightened oversight around controlled substances, the persistence of high-use counties raises a straightforward question: where pain burden, access constraints, and prescribing habits overlap, why do some places continue to rely more heavily on tramadol than others?

Dispensing rate declined by 35% over the study window, falling from 22.1 to 14.1 per 100 population. The statewide average annual tramadol dispensing rate was 17.90 per 100 population, but several counties sat well above that figure. Grant County posted an average annual rate of 34.10, McDowell County 28.91, and Wyoming County 26.67. Those county figures are not minor departures; they point to a durable geographic concentration of use even as the statewide trajectory moved downward.

One sentence captures the most important pattern in the dataset: tramadol use did not simply fade uniformly under tighter opioid oversight.

Social determinants lined up with higher dispensing rates

The regression results tied higher tramadol dispensing to county-level conditions that closely resemble broader measures of poor health and constrained access. Counties with a higher percentage of residents reporting poor or fair health had higher dispensing rates, with a coefficient of β = 0.07 and p = 0.01. Counties with more physically inactive residents also had higher tramadol dispensing, β = 0.10 with p = 0.0003. The association extended to insurance coverage, with higher dispensing in counties with more uninsured residents, β = 0.09 and p = 0.001.

Primary care supply also tracked with dispensing, and not in a way that suggests simple scarcity. Counties with elevated primary care provider rates had higher tramadol dispensing, β = 0.10 and p = 0.0003. That likely reflects greater treatment volume in areas with more clinical touchpoints rather than a straightforward shortage signal. It also suggests that tramadol may be entering the treatment pathway through routine outpatient pain management in places where chronic musculoskeletal pain, mobility limitation, and other untreated conditions are common. The strongest statistical association in the model was with the county opioid dispensing rate itself, β = 0.14 and p < 0.0001, linking tramadol to the broader opioid environment rather than isolating it as an outlier product.

Why tramadol sits in a difficult middle ground

Tramadol occupies a clinically awkward position. It is often perceived as safer than stronger opioids, yet the drug’s dual pharmacology and CYP2D6 dependence make its effects unpredictable. Poor metabolizers may receive inadequate pain relief and cycle through repeated prescriptions or add-on analgesics, while rapid metabolizers can generate higher active metabolite concentrations and face greater opioid toxicity. That variability helps explain why tramadol can remain common even in settings trying to reduce exposure to higher-potency opioids: it is often used as a compromise agent, especially when clinicians are balancing pain control against concern for misuse, respiratory depression, or dependence.

The study’s context in West Virginia also matters. Tramadol was placed into Schedule IV under the Controlled Substances Act in 2014, and state policy requires health professionals who prescribe or dispense Schedule II to V controlled substances to register with the Controlled Substances Monitoring Program. Additional opioid-prescribing safeguards introduced in 2018 added limits and consultation requirements. Even with those layers of oversight, dispensing patterns remained heterogenous. Administrative controls can suppress volume, but they do not erase the clinical and social drivers of pain treatment.

A single statewide average can hide a great deal of local variation.

Public health implications for local surveillance

The study points toward a surveillance strategy built at the county level rather than one guided only by state totals. Poor or fair health, physical inactivity, uninsured status, and higher opioid dispensing all aligned with higher tramadol use. In practical terms, those are markers of communities where pain burden, chronic disease, and access barriers may converge. If a county has both a high burden of poor health and a large uninsured population, tramadol may function as a low-cost, readily available option even when broader opioid reduction policies are in place.

The ecological design limits individual-level inference, but it still provides a useful map of where dispensing concentrates. It also suggests that tramadol should not be treated as clinically benign simply because it sits below Schedule II opioids on the regulatory ladder. In communities with high use, the medication may reflect deeper problems: inadequate chronic pain management, limited preventive care, reduced mobility, and continuing dependence on opioid-based symptom control.

The study’s operational takeaway is concrete. County health planning that ignores tramadol will miss a meaningful slice of opioid dispensing activity, especially in places already burdened by worse health status and lower insurance coverage. Tracking tramadol alongside broader opioid metrics may give public health officials a sharper picture of where prescribing pressure remains high and where pain-related need may still be going unmet.

The county signal is stronger than the statewide decline

West Virginia’s tramadol trend moved downward, but the decline did not flatten the geography of use. County differences remained pronounced, and the statistical associations tied tramadol to social and health conditions that are visible long before they appear in a pharmacy database. The study does not prove causation, and it does not identify which individual patients received the drug or why. It does show that tramadol dispensing is embedded in local patterns of health disadvantage and opioid exposure, and that makes it a useful marker for surveillance rather than a trivial prescribing footnote.

The report closes with a narrow but actionable message: if local health systems want to understand opioid use more completely, tramadol has to be counted in the picture, not left at the margins. The unanswered question is how much of the county variation stems from unmet pain needs, prescribing culture, or differential access to non-opioid alternatives, and that will require more granular patient-level work than an ecological dataset can provide.


Reporting by Dr. A.R. Athira, MBBS for Medicine World Foundation, with additional data provided by PLOS Medicine.
PRIMARY CLINICAL EVIDENCE & REGISTRY DATA